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Abstract
Background: Although colorectal cancer (CRC) is generally not considered to be a hormone-dependent malignancy,
several sex-related differences in incidence, molecular characteristics and survival have been reported. Epidemiological
studies have consistently shown that increased exposure to female sex hormones is associated with a lower risk of CRC
in women, and cyclin D1, an important downstream effector in estrogen-mediated signaling, is commonly activated in
CRC. In this study, we analyzed the prognostic significance of cyclin D1 expression in CRC, with particular reference to
sex-related differences, in tumors from a large, prospective, population-based cohort.
Methods: Using tissue microarrays and immunohistochemistry, the fraction and intensity of cyclin D1 expression
was evaluated in 527 incident CRC cases from the Malmö Diet and Cancer Study. The c
2 and Spearman’s rho (r)
tests were used for comparison of cyclin D1 expression and relevant clinicopathological characteristics. Kaplan-
Meier analysis and Cox proportional hazards modeling were used to assess the effect of cyclin D1 expression on
cancer-specific survival (CSS) in univariate and multivariate analysis, adjusted for established prognostic factors.
Results: Cyclin D1 intensity was significantly lower in male compared with female CRC (P = 0.018). In the full
cohort, cyclin D1 expression was associated with a significantly prolonged CSS (hazard ratio (HR) = 0.69; 95% CI
0.49 to 0.96, P = 0.026) but subgroup analysis according to gender revealed a strongly accentuated prognostic
effect of cyclin D1 in male CRC (HR = 0.48; 95% CI 0.31 to 0.74, P < 0.001), which was in contrast to female CRC,
where cyclin D1 was not prognostic (HR = 1.05; 95% CI 0.62 to 1.78, P = 0.864) (Pinteraction = 0.024). The prognostic
value of cyclin D1 was not retained in multivariate analysis, either in the full cohort or in male CRC.
Conclusions: Cyclin D1 expression is strongly associated with prolonged survival in male CRC. These findings not
only support an important role for cyclin D1 in colorectal carcinogenesis, but also add further weight to the
accumulating evidence that CRC is indeed a hormone-dependent malignancy, for which prognostic and treatment-
predictive molecular biomarkers should be evaluated differently in women and men.
Background
Colorectal cancer (CRC) is one of the most common
forms of human cancer worldwide, with approximately
1 million new cases detected every year [1]. Early detec-
tion, adequate surgical excision and optimal adjuvant
treatment are of crucial importance if a favorable
outcome is to be achieved. Currently, tumor stage at
d i a g n o s i si st h em o s ti m p o r t a n tp r o g n o s t i cf a c t o ri n
CRC, and although many efforts have been made to find
molecular markers to identify high-risk disease and to
select patients for adjuvant treatment, none has proven
sufficiently good for use in clinical routine.
Several sex-related differences in the incidence [2],
survival chemotherapeutic response [4] and certain
molecular characteristics [5,6] of CRC have been
reported. Furthermore, large-scale population-based
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shown a significant reduction in both the risk and rate
of developing CRC in post-menopausal women treated
with combined hormone replacement therapy (HRT)
[7], and both pregnancy and the oral contraceptive pill
are associated with a reduced CRC risk [8,9]. Taken
together, these data suggest that estrogens and/or pro-
gestins have a protective effect against colorectal carci-
nogenesis, although the molecular mechanisms behind
these observations are not yet fully understood. The
effects of estrogens are mediated by estrogen receptors
(ERs), of which two (ERa and ERb)e x i s t ,w i t hE R b
being the predominant ER expressed in CRC [10-12].
Cyclin D1 is an important cell-cycle regulating protein
that, together with its binding partners cyclin-dependent
kinase (CDK)4 and CDK6, forms active complexes that
promote G1- to S-phase progression by phosphorylating
and inactivating the retinoblastoma protein [13]. More
recent studies have also revealed important CDK-inde-
pendent functions of cyclin D1 in the regulation of sev-
eral transcription factors [14], as first shown for the ER
[15,16]. Cyclin D1 overexpression is common in CRC,
but the findings regarding its prognostic value are con-
flicting [17-29]. However, the largest study to date, com-
prising an analysis of 602 tumors from two independent,
prospective cohort studies, found an association between
cyclin D1 overexpression and a prolonged survival from
colon cancer [29].
Cyclin D1 is activated by WNT/b-catenin signaling
after mutation of the adenomatous polyposis coli gene
(APC), an important event in the initiation of colorectal
neoplasia [30,31]. WNT/b-catenin signaling is modu-
lated by estrogens in breast cancer [32] and neuronal
cells [33], and endogenous estrogens have been found to
protect against APC-associated tumor formation in
mice, associated with an increase in ERb and a decrease
in ERa expression in the target tissue [34]. Moreover,
whereas both ERa and ERb deficiency have been asso-
ciated with enhanced intestinal neoplasia in mice carry-
ing APC mutations, only ERa deficiency was associated
with activation of WNT/b-catenin signaling [35], and
functional studies in CRC cells have demonstrated anti-
proliferative and antitumorigenic effects of ERb overex-
pression, despite a functional link to increased cyclin D1
levels [36]. A potential involvement of cyclin D1 in the
pathway to CRC, involving mismatch repair, has also
been suggested [37], and in the study by Ogino et al.,
an interaction between cyclin D1 expression and micro-
satellite instability (MSI) status was reported; the pre-
s e n c eo fe i t h e rc y c l i nD 1o rh i g hM S I ,o rb o t h ,w a s
associated with a better prognosis [29].
Because cyclin D1 expression is modulated by hormo-
nal activity, we hypothesized that its expression and
prognostic effects might differ according to gender in
CRC. The aim of this study was therefore to analyze the
immunohistochemical expression and prognostic signifi-
cance of cyclin D1, with particular reference to sex-
related differences, in 626 incident cases of CRC in the
prospective, population-based cohort Malmö Diet and
Cancer Study (MDCS) [38], from which 557 tumors had
been assembled in tissue microarrays (TMAs).
Methods
Ethics approval for the MDCS (reference 51/90) and the
present study (reference 530/2008), were obtained from
the Ethics Committee at Lund University.
The Malmö Diet and Cancer Study
The MDCS is a population-based, prospective cohort
study with the main aim to examine whether a western
diet rich in fat and low in fruit and vegetables increases
the risk of certain forms of cancer [38]. Between 1991
and 1996, a total of 28,098 participants (11,063 men
(39.4%) and 17.035 women (60.6%)) aged between 44
and 74 years where enrolled (from a background popu-
lation of 74,138). Follow-up is performed annually by
record linkage to national registries for cancer and
cause of death.
Incident colorectal cancer until 31 December 2008
Until the end of follow-up on 31 December 2008, 626
incident cases of CRC had been registered in the study
population. Cases were identified from the Swedish Can-
cer Registry until 31 Dec 2007 and from the Southern
Swedish Regional Tumour Registry for the period 1 Jan-
uary to 31 December 2008. All tumors for which slides
or paraffin wax tissue blocks were available were histo-
pathologically re-evaluated using hematoxylin and eosin
staining. Histopathological, clinical and treatment data
were obtained from the clinical- and/or pathology
records. Information on vital status and cause of death
was obtained from the Swedish Cause of Death Registry
until 31 Dec 2009. Follow-up started at date of diagnosis
and ended at death, emigration or 31 December 2009,
whichever came first.
Tissue microarray construction
In total, 557 (89.0%) tumors were available and suitable
for TMA construction (see Additional File 1). Areas
representative of cancer were marked on hematoxylin
and eosin-stained slides, and TMAs were constructed as
previously described [39]. In brief, two 1.0 mm cores
were taken from each tumor and mounted in a new
recipient block using a semi-automated arraying device
(TMArrayer; Pathology Devices, Westminster, MD,
USA).
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Page 2 of 10Table 1 Patient and tumor characteristics in the evaluated cohort and in subgroups according to gender
All, n = 527 Female, n = 276 (52.4%) Male, n = 251 (47.6%) P value
a
Age
Mean 70.5 70.6 70.4 0.399
Median 71.4 72 70.9
Range 49.8 to 85.6 49.8 to 85.2 51.8 to 85.6
Location
Colon 323 (61.3) 176 (63.8) 147 (58.6) 0.256
Rectum 190 (36.1) 92 (33.3) 98 (39.0)
Multiple 12 (2.3) 7 (2.5) 5 (2.0)
Unknown 2 (0.4) 1 (0.4) 1 (0.4)
T Stage
1 46 (8.7) 31 (11.2) 15 (6.0) 0.506
2 63 (12.0) 30 (10.9) 33 (13.1)
3 319 (60.5) 159 (57.6) 160 (63.7)
4 78 (14.8) 42 (15.2) 36 (14.3)
Unknown 21 (4.0) 39 (12.0) 38 (12.7)
N stage
0 278 (52.8) 144 (52.2) 134 (53.4) 0.494
1 118 (22.4) 68 (24.6) 50 (19.9)
2 85 (16.1) 36 (13.0) 49 (19.5)
Unknown 46 (8.7) 28 (10.1) 18 (7.2)
M Stage
0 429 (81.4) 226 (81.9) 203 (80.9) 0.513
1 90 (17.1) 44 (15.9) 46 (18.3)
Unknown 8 (1.5) 6 (2.2) 2 (0.8)
Differentiation grade
High 34 (6.5) 19 (6.9) 15 (6.0) 0.438
Intermediate 367 (69.6) 185 (67.0) 182 (72.5)
Low 118 (22.4) 67 (24.3) 51 (20.3)
Unknown 8 (1.5) 5 (1.8) 3 (1.2)
Vascular invasion
No 150 (28.5) 81 (29.3) 69 (27.5) 0.635
Yes 156 (29.6) 80 (29.0) 76 (30.3)
Unknown 222 (41.9) 115 (41.7) 106 (42.2)
Surgery
Acute 46 (8.7) 26 (9.4) 20 (8.0) 0.502
Elective 454 (86.1) 233 (84.4) 221 (88.0)
Unknown 27 (5.1) 17 (6.2) 10 (4.0)
Neodjuvant treatment
None 414 (78.6) 216 (83.4) 198 (82.2) 0.291
Short RT 25 (4.7) 10 (3.9) 15 (6.2)
Long RT 19 (3.6) 8 (3.1) 11 (4.6)
Chemotherapy + RT 2 (0.4) 2 (0.8) 0 (0.0)
Chemotherapy 2 (0.4) 1 (0.4) 1 (0.4)
Unknown 65 (12.3) 39 (14.1) 16 (10.4)
Adjuvant treatment
No 294 (55.8) 149 (54.0.8) 145 (57.8) 0.584
FLV/Xeloda 51 (9.7) 25 (9.1) 26 (10.4)
FLOX/XELOX 19 (3.6) 11 (4.0) 8 (3.2)
Other 5 (0.9) 4 (1.4) 1 (0.4)
Curative; M1* 14 (2.7) 6 (2.2) 8 (3.2)
Palliative 80 (15.2) 39 (14.1) 41 (16.3)
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staining
For immunohistochemical analysis, 4 μmT M As e c t i o n s
were automatically pretreated using a pretreatment
module (PT-Link; Dako, Glostrup, Denmark) and then
stained (Autostainer Plus; Dako) with the monoclonal
anti-cyclin D1 antibody DSC-6 (Dako), diluted 1:50.
This antibody has been validated and used for staining
of formalin-fixed paraffin wax-embedded tissue in sev-
eral previous studies [40-42].
We recorded the intensity of nuclear cyclin D1
expression (no, weak, moderate or strong), and the pro-
portion of positive tumor cells (0 = 0 to 1%, 1 = 2 to
25%, 2 = 26 to 50%, 3 = 51 to 75%) and 4 = > 75%). For
further statistical analyses, cyclin D1 expression was
dichotomized into negative (no expression and positive
(any expression; fraction and intensity). The staining
was evaluated by two independent observers (SW and
KJ), who were blinded to the clinical and outcome data.
Any scoring differences were discussed in order to reach
consensus.
Statistical analysis
The c
2 and Spearman’s r tests were used for compari-
son of cyclin D1 expression and relevant clinicopatholo-
gical characteristics. Kaplan-Meier analysis and log-rank
test were used to illustrate differences in cancer-specific
survival (CSS) according to cyclin D1 expression. Cox
regression proportional hazards models were used for
estimation of hazard ratio (HR) for death from CRC
according to cyclin D1 expression in both univariate
and multivariate analyses, adjusted for age, gender,
TNM stage, differentiation grade and vascular invasion.
The interaction between cyclin D1 expression and gen-
der was explored by a Cox model including the interac-
tion variable. All survival analyses were repeated with
overall mortality as endpoint and all tests were two-
sided. P < 0.05 was considered significant. All statistical
Table 1 Patient and tumor characteristics in the evaluated cohort and in subgroups according to gender (Continued)
Unknown 64 (12.1) 42 (15.2) 22 (8.8)
Follow-up (years)
Mean 4.7 4,9 4.5 0.399
Median 3.5 3.4 3.4
Range 0.0 to 17.7 0.0 to 17.7 0.0 to 16.6
Vital status
Alive 306 (58.1) 169 (61.2) 137 (54.6) 0.113
Dead 221 (41.9) 107 (38.8) 114 (45.4)
Dead from CRC 182 (34.5) 90 (32.6) 92 (36.7) 0.313
Follow-up (years); M1 patients
Mean 1.5 1.3 1.6 0.129
Median 1.1 0.8 1.2
Range 0.0 to 6.1 0.0 to 5.5 0.0 to 6.1
Vital status; M1 patients
Alive 12 (13.3) 7 (15.9) 5 (10.9) 0.484
Dead 78 (86.7) 37 (84.1) 41 (89.1)
Dead from CRC 78 (86.7) 37 (84.1) 41 (89.1) 0.484
Cyclin D1 fraction
0 to 1 105 (19.9) 50 (18.1) 55 (21.9) 0.217
02 to 25 195 (37.0) 100 (36.2) 95 (37.8)
26 to 50 86 (16.3) 48 (17.4) 38 (15.1)
51 to 75 112 (21.3) 64 (23.2) 48 (19.1)
> 75 29 (5.5) 14 (5.1) 15 (6.0)
Cyclin D1 intensity
Negative 105 (19.9) 50 (18.1) 55 (21.9) 0.018
Weak 181 (34.3) 85 (30.8) 96 (38.2)
Moderate 176 (33.4) 102 (37.0) 74 (29.5)
Strong 65 (12.3) 39 (14.1) 26 (10.4)
aThe P values refer to comparisons of male and female tumors, using the Mann-WhitneyU-test for comparison of medians and the c
2 test for X × 2 tables. P-
values for vital status refer to overall and cause-specific death, respectively. The categories marked as ‘not done’ and ‘unknown’ were not included in the
statistical analysis.
Abbreviations: FLOX = 5-fluorouracil, leucovorin and oxaliplatin, FLV = 5-fluorouracil and leucovorin, RT = radiotherapy, XELOX = Xeloda (capecitabine) and
oxaliplatin.
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18; SPSS Inc, Chicago, IL, USA).
Results
Distribution of clinicopathological characteristics and
cyclin D1 expression in the full cohort and in subgroups
according to gender
There was no significant difference in the distribution of
clinicopathological characteristics or treatment in sub-
groups according to gender (Table 1). The distribution
of clinicopathological characteristics did not differ
between the full cohort (n = 626) and the evaluated
cohort (n = 527) (data not shown). There was no sex-
related difference in survival for patients with metastatic
CRC (Table 1). After antibody optimization and stain-
ing, cyclin D1 expression could be evaluated in 527of
557 tumors (94.6%) represented in the TMA. The tissue
cores that could not be evaluated either had been lost
during immunohistochemical processing or did not con-
tain invasive cancer.
Representative immunohistochemistry images are
shown in Figure 1. Cyclin D1 expression was only rarely
seen in inflammatory cells and stromal cells. Of the 527
tumors evaluated, 105 (16.8%) were negative for cyclin
D1; in the remaining tumors, cyclin D1 was expressed
in various fractions and intensities (Table 1). The inten-
sity but not the fraction of cyclin D1 was significantly
lower in male compared with female CRC (P = 0.018).
Association between Cyclin D1 expression and
clinicopathological characteristics in the full cohort and
the subgroups according to gender
Next, we examined the relationship between cyclin D1
expression (fraction and intensity) and established clin-
icopathological parameters in all patients, both female
and male (Table 2). We found a significant inverse
correlation between cyclin D1 fraction (but not inten-
sity) and the N (R = -0.014, P =0 . 0 1 2 )a n dM( R =
-0.091, P = 0.039) stages in the full cohort. This asso-
ciation was not evident in women, but in men, both
the fraction and intensity of cyclin D1 staining were
inversely correlated with N stage (R = -0.134, P =
0.041 for fraction and R = -0.153, P =0 . 0 2 0f o ri n t e n -
sity) and M stage (R = -0.143, P = 0.024 for fraction
and R = -0.161, P = 0.011 for intensity). In the full
cohort, but not in subgroups according to gender,
t h e r ew a sap o s i t i v ea s s o c iation between cyclin D1
fraction (but not intensity) and age (R = 0.101, P =
0.020), and an inverse association with T stage (R =
-0.105, P = 0.018). Cyclin D1 fraction, but not inten-
sity, was also inversely associated with vascular inva-
sion in the full cohort (R = -0.121, P = 0.034) and in
women (R = -0.175, P = 0.026), but not in men.
Association between cyclin D1 expression and survival
The prognostic value of established clinicopathological
parameters did not differ between women and men (see
Additional File 2). Kaplan-Meier analysis showed that
cyclin D1 expression, both fraction and intensity, was
associated with a stepwise improvement in CSS in all
patients (Figure 2A and 2B). However, subgroup analysis
according to gender showed that this association was
not significant in female patients (Figure 2C and 2D)
but was highly significant, and even accentuated, in
male patients (Figure 2E and 2F). These associations
were confirmed in univariate Cox regression analysis
(Table 3) but did not remain significant in multivariate
analysis adjusted for age, gender, TNM, differentiation
grade and vascular invasion (Table 3). The results were
not significantly altered when vascular invasion or cases
with missing information on vascular invasion were
excluded from the analysis (data not shown).
Cox interaction analysis confirmed a significant interac-
tion between cyclin D1 status and gender (pinteraction =
0.024), which was not retained when adjusted for con-
ventional prognostic markers (Table 3). Next, we
Figure 1 Immunohistochemical images of cyclin D1 staining in
colorectal cancer. (A,B) Negative staining, (C,D) various fractions of
weak to moderate staining, and (D-F) strong cyclin D1 staining.
Original magnification × 20.
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D1 status, which showed that, in the full cohort, men
with cyclin D1-negative tumors had a significantly
impaired CSS compared with men with cyclin D1-posi-
tive tumors and compared with all women, irrespective
of cyclin D1 status (Figure 3A). These associations were
not evident in subgroup analysis of patients with stage
I-II disease (Figure 3B), but remained significant for
patients with stage III-V disease (Figure 3C). In patients
with stage III (T1-4, N1-2, M0) disease (n = 126), of
whom 65 (51.6%) had received adjuvant chemotherapy
and 61 (48.4%) had not, the prognostic value of cyclin
D1 was not altered by adjuvant chemotherapy, either in
all patients or in subgroup analysis according to gender
(data not shown).
The sex-related effect on survival of cyclin D1 expres-
sion did not differ between cancers of the colon and
rectum (data not shown).
For all analyses, similar associations were seen using
overall survival, that is, death from any cause, as end-
point (data not shown).
Discussion
In this study, we found that cyclin D1 expression was
associated with a more favorable outcome from CRC in
a large, population-based cohort study, confirming pre-
vious findings [29]. However, subgroup analysis accord-
ing to gender revealed that the prognostic value of
cyclin D1 was only evident in male but not female CRC
patients, a finding that has, to our knowledge, not been
reported previously. It will be of interest for future stu-
dies to investigate the molecular basis for this contrast-
ing prognostic significance of cyclin D1 expression in
women and men, with particular reference to the influ-
ence of sex-hormone levels, anthropometric factors, and
genetic and epigenetic modification of steroid receptors.
Although the distribution of conventional clinico-
pathological and prognostic factors did not differ
between female and male CRC patients in this study,
the proportion of tumors with strong cyclin D1 intensity
was significantly lower in the group of tumors from
male patients. This association is interesting, given the
protective effect of estrogen against CRC and the
Table 2 Associations between cyclin D1 expression and clinicopathological characteristics in all patients, females and
males
All Female Male
Cyclin D1 fraction Cyclin D1 intensity Cyclin D1 fraction Cyclin D1 intensity Cyclin D1 fraction Cyclin D1 intensity
Age
R 0.101 0.064 0.111 0.090 0.083 0.022
P value 0.020* 0.142 0.065 0.134 0.189 0.73
n 527 527 276 277 251 251
T stage
R -0.105 -0-086 -0.105 -0.072 -0.104 -0.098
P value 0.018* 0.053 0.09 0.245 0.107 0.128
n 506 506 262 262 244 244
N stage
R -0.114 -0.079 -0.094 -0.003 -0.134 -0.153
P value 0.012* 0.085 0.140 0.962 0.041* 0.020*
n 481 481 248 248 233 233
M stage
R -0.091 -0.064 -0.039 0.030 -0.143 -0.161
P value 0.039* 0.147 0.520 0.628 0.024* 0.011*
n 519 520 270 270 249 249
Differentiation grade
R -0.051 0.044 -0.095 0.007 -0.004 0.076
P value 0.243 0.310 0.116 0.908 0.948 0.232
n 527 527 276 276 251 251
Vascular invasion
R -0.121 -0.068 -0.175 -0.109 -0.065 -0.018
P value 0.034* 0.233 0.026* 0.167 0.435 0.830
n 306 306 161 1611 145 145
Abbreviations: n = number (sample size); R = Spearman’s correlation coefficient.
*Significant at the 0.05 level; **Significant at the 0.01 level.
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Page 6 of 10Figure 2 Association between cyclin D1 expression and survival in all patients and in subgroups according to gender. Kaplan-Meier
analysis of colorectal cancer-specific survival according to cyclin D1 fraction and intensity, respectively, in (A,B) all patients, (C,D) female patients
and (E,F) male patients.
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Page 7 of 10important role of cyclin D1 as a mediator of estrogen
signaling. Notably, the majority of the female cohort
examined in this study was post-menopausal, either hav-
ing low/no circulating estrogens or taking HRT.
Until further knowledge about the role of cyclin D1 in
CRC has been gained, we believe that evaluation of the
fraction and intensity of cyclin D1 as separate categories
makes sense, not least in light of previous studies in
breast cancer, for which the intensity, but not fraction,
of cyclin D1 expression was found to influence survival
and response to antihormonal therapy [40,43]. However,
in our study, there was a similar effect of cyclin D1 on
survival for both fraction and intensity, with a stepwise
improvement from negative to high expression.
The association between cyclin D1 expression and
clinicopathological parameters differed somewhat
according to gender, with a significant inverse relation-
ship between cyclin D1 expression and N and M stages
in male but not female CRC, indicating that lack of
cyclin D1 is associated with a more aggressive pheno-
type in male patients. However, this interpretation is
somewhat dampened by the inverse association we
observed between cyclin D1 expression and vascular
invasion, another adverse prognostic factor, in female
but not male CRC.
In contrast to the findings in the study by Ogino et al.
[29], cyclin D1 expression did not remain an indepen-
dent prognostic factor in multivariate analysis in our
Table 3 Cox univarate and multivariate proportional hazards analysis of colorectal cancer-specific survival in all
patients
Cyclin D1 expression Univariate Multivariate
HR (95%CI) n (events) PP
a HR (95%CI) n (events) P
b P
c
All patients
Low 1.00 105 (48) 1.00 99 (45)
High 0.69 (0.49 to 0.96) 422 (134) 0.026 0.024 1.08 (0.75 to 1.58) 377 (113) 0.671 0.429
Female
Low 1.00 50 (17) 1.00 47 (16)
High 1.05 (0.62 to 1.78) 226 (73) 0.864 1.35 (0.75 to 2.41) 199 (60) 0.313
Male
Low 1.00 55 (31) 1.00 52 (29)
High 0.48 (0.31 to 0.74) 196 (61) < 0.001 0.90 (0.53 to 1.53) 178 (53) 0.712
Abbreviations: HR = hazard ratio.
aP value from multivariate analysis adjusted for T stage (1 to 2 versus 3 to 4), N stage (0 versus 1 to 2), M stage (0 versus1), age (≤ or ≥ 75 years), differentiation
grade (high to intermediate versus low) and vascular invasion (absent, present, missing). Sex was included in the multivariate analysis for all patients.
bP value for term of interaction by Cox multivariate analysis including gender, the binary covariate cyclin D1 expression and a term of interaction.
cP value for term of interaction adjusted for T stage (1 to 2 versus 3 to 4), N stage (0 versus 1 to 2), M stage (0 versus1), age (≤ or ≥ 75 years), differentiation
grade (high to intermediate versus low) and vascular invasion (absent, present, missing).
Figure 3 Kaplan-Meier estimates of colorectal cancer-specific survival according to combinations of gender and positive versus
negative cyclin D1 expression. Colorectal cancer-specific survival in (A) all patients, (B) patients with stage I-II disease and (C) patients with
stage III-IV disease. Log-rank P values correspond to pairwise comparisons of cyclin D1-negative tumors in male patients with the other strata,
respectively.
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Page 8 of 10study, either in the full cohort or in the male group. The
association between cyclin D1 expression and more
favorable clinicopathological features might in part
explain the lack of an independent prognostic value for
cyclin D1 in male CRC, although the sex-related prog-
nostic effect of cyclin D1 was evident in patients with
stage III-IV disease but not in patients with stage I-II
disease. Owing to the relatively small subgroups, these
findings should be interpreted with caution, but it is
noteworthy that a similar association was found by
Ogino et al. [29]. The reason for this remains unclear,
but it could be speculated that, although they are in a
disseminated state, cyclin D1-expressing tumors are still
less aggressive than tumors lacking cyclin D1 expres-
sion. This assumption is supported by previous studies
in breast cancer, which showed an association between
low cyclin D1 levels and a more invasive tumor pheno-
type [42]. Another explanation for the more evident
beneficial prognostic effect of cyclin D1 in metastatic
disease could be that cyclin D1 expression predicts
response to adjuvant chemotherapy. However, we could
not find such an effect when the prognostic influence of
cyclin D1 expression was analyzed in the subgroup of
patients with stage III disease, of whom a relatively large
proportion had not received adjuvant chemotherapy.
Because the MDCS is a population-based cohort study,
a potential selection bias compared with the general
population must be taken into consideration [38]. The
denoted frequency of acute surgery was 8.7% (8.3% in the
full cohort of 626 cases), which is lower than the usually
reported frequency of approximately 25% [44,45]. This is
noteworthy as it could reflect a higher awareness of CRC
among study participants. However, information on sur-
gery was missing for 5.1% of the patients (8.6% in the full
cohort), and lower frequencies have been reported in
other studies [46]. Furthermore, the distribution of clini-
cal stages at diagnosis in our study is in line with that
expected, with no favoring of less advanced stages.
In this study, we used CRC-specific survival as the pri-
mary endpoint. Notably, all associations between cyclin
D1 expression and survival were similar when overall
survival was used as the endpoint, and because the
number of events for cancer-specific and overall survival
was identical for patients with metastatic disease, with a
median survival of approximately 10.5 months (range 0
to 72), the use of CSS should be a reasonable surrogate
for cancer-specific outcome. In future studies, the effect
of cyclin D1 expression on recurrence-free survival
should also be assessed, preferably in cohorts in which
this information has been recorded prospectively.
Conclusions
The results from this large cohort study show that tumor-
specific cyclin D1 expression is strongly associated with a
p r o l o n g e ds u r v i v a lf r o mC R Ci nm e nb u tn o tw o m e n .
These findings not only suggest an important role for cyclin
D1 in colorectal carcinogenesis and progression, but also
add support to the accumulating evidence that sex hor-
mones are relevant to the development of CRC, and that
prognostic and treatment-predictive molecular biomarkers
should be evaluated differently in women and men.
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